This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.
Produkteigenschaften
- Artikelnummer: 9783319561967
- Medium: Buch
- ISBN: 978-3-319-56196-7
- Verlag: Springer International Publishing
- Erscheinungstermin: 27.07.2017
- Sprache(n): Englisch
- Auflage: 1. Auflage 2017
- Serie: Resistance to Targeted Anti-Cancer Therapeutics
- Produktform: Gebunden, HC runder Rücken kaschiert
- Gewicht: 3731 g
- Seiten: 147
- Format (B x H x T): 160 x 241 x 15 mm
- Ausgabetyp: Kein, Unbekannt